StockWatch
·
Medical/Dental Instruments
Quarterly ResultNov 3, 2026, 04:06 PM

AtriCure Q3 Revenue $154.5M (+15% YoY); Net Income $4.1M

AI Summary

AtriCure, Inc. announced its third quarter 2026 financial results, reporting a 15.0% year-over-year increase in worldwide revenue to $154.5 million. U.S. revenue grew by 17.1% to $128.0 million, primarily due to strong sales of pain management and ablation devices. The company achieved profitability in the quarter with a net income of $4.1 million ($0.08 per diluted share) and an adjusted EBITDA of $26.8 million, marking a 51% increase. Gross margin also saw improvement, reaching 77.3%. AtriCure updated its full-year 2026 financial guidance, projecting revenue between $606 million and $610 million and adjusted EBITDA between $91 million and $94 million. The company also highlighted progress in its BoxX-NoAF clinical trial.

Key Highlights

  • AtriCure reported Q3 2026 worldwide revenue of $154.5 million, up 15.0% year-over-year.
  • U.S. revenue increased 17.1% to $128.0 million, driven by cryoSPHERE MAX, EnCompass, and AtriClip devices.
  • Third quarter 2026 net income was $4.1 million, or $0.08 per diluted share, compared to a net loss of $0.01 per share in Q3 2025.
  • Adjusted EBITDA for Q3 2026 was $26.8 million, a 51% increase from Q3 2025.
  • Gross margin improved to 77.3% in Q3 2026, up 180 basis points year-over-year.
  • Full year 2026 revenue guidance revised to $606-$610 million; adjusted EBITDA projected at $91-$94 million.